Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease"
- PMID: 33852949
- DOI: 10.1016/j.jhep.2021.03.027
Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease"
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that refer to this letter. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.J Hepatol. 2021 Apr;74(4):819-828. doi: 10.1016/j.jhep.2020.10.004. Epub 2020 Oct 16. J Hepatol. 2021. PMID: 33075344
-
Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease.J Hepatol. 2021 Jul;75(1):232-234. doi: 10.1016/j.jhep.2021.01.016. Epub 2021 Jan 21. J Hepatol. 2021. PMID: 33484772 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical